Gilead Sciences Chief Medical Officer to Step Down
Provided by
Dow Jones
By Michael Susin
Gilead Sciences on Wednesday said its Chief Medical Officer Merdad Parsey will leave the company early next year.
The biopharmaceutical company said Parsey will continue in the role until the first quarter of 2025 and support this transition over the next several months.
Parsey joined the Gilead in November 2019 and is responsible for overseeing the company's global clinical development and medical affairs organizations.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
July 17, 2024 09:19 ET (13:19 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks
United States